Pediatric Infection and Vaccine

  • 제16권2호
  • /
  • Pages.107-114
  • /
  • 2009
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지

소아청소년의 결핵 감염과 질병에 대한 최신 지견

Update on Tuberculosis in Children and Adolescents

  • 김종현 (가톨릭대학교 의과대학 소아과학교실)
  • Kim, Jong Hyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 투고 : 2009.06.30
  • 심사 : 2009.12.01
  • 발행 : 2009.12.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Tuberculosis is a disease with high morbidity and mortality in children worldwide. Despite significant improvements in diagnostic methods, scientific researches and clinical trials for new regimens of treatment or prevention in adult tuberculosis, childhood tuberculosis has been relatively neglected. Children are at high risk of severe disease, and reactivation of latent infection in adulthood perpetuates the epidemic. Therefore, a policy of tuberculosis control in childhood should be emphasized to improve control in the total population. To understand the new view of childhood tuberculosis, this article describes changes in the disease's national epidemiology, new diagnostic tools and treatment strategies, and multi-drug resistance.

키워드

참고문헌

  1. Brent AJ, Anderson ST, Kampmann B. Childhood tuberculosis: out of sight, out of mind? Trans R Soc Trop Med Hyg 2008;102:217-8. https://doi.org/10.1016/j.trstmh.2007.09.011
  2. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med 2006;173:1078-90. https://doi.org/10.1164/rccm.200511-1809SO
  3. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(RR-6):1-51.
  4. Starke JR. New concepts in childhood tuberculosis. Curr Opin Pediatr 2007;19:306-13. https://doi.org/10.1097/MOP.0b013e32814b164a
  5. World Health Organization. WHO Report 2007: Global Tuberculosis Control (Surveillance, Planning, Financing). Geneva : WHO, 2007.
  6. Korea Centers for Disease Control and Prevention. Elimination of TB 2030. Seoul : Korea Centers for Disease Control and Prevention, 2008.
  7. Korea Centers for Disease Control and Prevention, Korean Institute of Tuberculosis. Annual Report on the Tuberculosis Cases Notified in Korea, 2005. Seoul: Korea Centers for Disease Control and Prevention, 2006.
  8. Kim JH. Evaluation for the usefulness of BCG vaccine: a survey for prevalence change of disseminated tuberculosis in children. Seoul : Korea Food and Drug Administration. 2007:42-6.
  9. Stop TB Partnership Childhood Tuberculosis Subgroup. Chapter 1: introduction and diagnosis of tuberculosis in children. Int J Tuberc Lung Dis 2006;10:1091–7.
  10. Zar HJ, Hanslo D, Apollos P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005;365: 130-4. https://doi.org/10.1016/S0140-6736(05)17702-2
  11. Hoskyns W. Paediatric tuberculosis. Postgrad Med J 2003;79:272-8. https://doi.org/10.1136/pmj.79.931.272
  12. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006;10:1192-204.
  13. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London : Royal College of Physicians, 2006:105-16.
  14. Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON$^{\circledR}$-TB Gold Test for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(RR-15):49-55.
  15. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54. https://doi.org/10.7326/0003-4819-146-5-200703060-00006
  16. Davies PDO, Drobniewski F. The use of interferon-$\gamma$- based blood tests for the detection of latent tuberculosis infection. Eur Respir J 2006;28:1-3. https://doi.org/10.1183/09031936.06.00047606
  17. Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian Refugees. A five-year surveillance study. Am Rev Respir Dis 1988;137:805-9. https://doi.org/10.1164/ajrccm/137.4.805
  18. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 2006;6:413- 22. https://doi.org/10.1586/14737159.6.3.413
  19. Machado A Jr, Emodi K, Takenami I, Finkmoore BC, Barbosa T, Carvalho J, et al. Analysis of discordance between the tuberculin skin test and the interferongamma release assay. Int J Tuberc Lung Dis 2009;13: 446-53.
  20. O'Neal S, Hedberg K, Markum A, Schafer S. Discordant tuberculin skin and interferon-gamma tests during contact investigations: a dilemma for tuberculosis controllers. Int J Tuberc Lung Dis 2009;13:662-4.
  21. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004;8:392–402.
  22. Marais BJ, Gie RP, Schaaf HS, Starke JR, Hesseling AC, Donald PR, et al. A proposed radiological classification of childhood intra-thoracic tuberculosis. Pediatr Radiol 2004;34:886-94. https://doi.org/10.1007/s00247-004-1238-0
  23. Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Enarson DA, Beyers N. Radiographic signs and symptoms in children treated for tuberculosis: possible implications for symptom-based screening in resource-limited settings.Pediatr Infect Dis J 2006;25:237-40. https://doi.org/10.1097/01.inf.0000202140.76368.74
  24. Stop TB Partnership Childhood TB Subgroup, World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Chapter 2: anti-tuberculosis treatment in children. Int J Tuberc Lung Dis 2006;10:1205-11.
  25. Donald PR, Mahar D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis 2006;10: 1318-30.
  26. Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005;90:614-8. https://doi.org/10.1136/adc.2004.052175
  27. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva : WHO, 2008:135-9.
  28. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11: 571-6.
  29. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non–HIV-infected patients with multidrug- resistant tuberculosis. Clin Infect Dis 2007;45: 1290-5. https://doi.org/10.1086/522537
  30. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drugresistant tuberculosis. Clin Infect Dis 2008;47:496-502. https://doi.org/10.1086/590005
  31. Stevens JP, Daniel TM. Chemoprophylaxis of multidrugresistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide: a decision analysis. Chest 1995;108:712–7. https://doi.org/10.1378/chest.108.3.712
  32. Horn DL, Hewlett D Jr, Alfalla C, Peterson S, Opal SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994;330: 1241.
  33. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002;109;765-71. https://doi.org/10.1542/peds.109.5.765
  34. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161 Suppl:221-47. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600